Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


08.10.2018

2 Br J Nurs
1 Bull Cancer
2 Can J Urol
1 Can Urol Assoc J
1 Cancer Invest
1 Dis Markers
5 Eur Urol
1 Indian J Med Res
1 Indian J Pathol Microbiol
2 Int J Mol Sci
1 J Clin Neurosci
1 J Cutan Pathol
1 J Vet Intern Med
1 J Vis Exp
2 Medicine (Baltimore)
1 Mol Cancer
1 Mol Med Rep
2 Onco Targets Ther
1 Oncol Rep
2 Urol Int
1 Urology
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Nurs

  1. JOSE S
    Bladder cancer: an overview of treatments.
    Br J Nurs. 2018;27:S28-S30.
    PubMed     Text format    

  2. ANDERSON B
    Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer.
    Br J Nurs. 2018;27:S8-S20.
    PubMed     Text format     Abstract available


    Bull Cancer

  3. SOUAID T, Hindy JR, Eid R, Kourie HR, et al
    Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful.
    Bull Cancer. 2018 Sep 26. pii: S0007-4551(18)30236.
    PubMed     Text format     Abstract available


    Can J Urol

  4. SIRACUSANO S, Silvestri T, Bassi S, Porcaro AB, et al
    Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer.
    Can J Urol. 2018;25:9480-9485.
    PubMed     Text format     Abstract available

  5. ZILLIOUX J, DiLizia M, Schaheen B, Rustin R, et al
    Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer.
    Can J Urol. 2018;25:9525-9526.
    PubMed     Text format     Abstract available


    Can Urol Assoc J

  6. WEI X, Siemens DR, Mackillop WJ, Booth CM, et al
    Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns.
    Can Urol Assoc J. 2018 Sep 27. pii: cuaj.5447. doi: 10.5489/cuaj.5447.
    PubMed     Text format     Abstract available


    Cancer Invest

  7. SEYEDABADI S, Saidijam M, Najafi R, Mousavi-Bahar SH, et al
    Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals.
    Cancer Invest. 2018 Oct 2:1-8. doi: 10.1080/07357907.2018.1514504.
    PubMed     Text format     Abstract available


    Dis Markers

  8. WANG ZY, Li HY, Wang H, Chi Q, et al
    Bladder Cancer-Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection.
    Dis Markers. 2018;2018:5609395.
    PubMed     Text format     Abstract available


    Eur Urol

  9. TAN WS, Panchal A, Buckley L, Devall AJ, et al
    Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gueri
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30655.
    PubMed     Text format     Abstract available

  10. ARENDS TJH, Witjes JA
    Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bac
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30647.
    PubMed     Text format    

  11. ABEYSIRI S, Richards T
    Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36:
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30664.
    PubMed     Text format    

  12. CUMBERBATCH MGK, Jubber I, Black PC, Esperto F, et al
    Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30651.
    PubMed     Text format     Abstract available

  13. WARRICK JI, Sjodahl G, Kaag M, Raman JD, et al
    Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30653.
    PubMed     Text format     Abstract available


    Indian J Med Res

  14. TOKARZEWICZ A, Guszcz T, Onopiuk A, Kozlowski R, et al
    Utility of cystatin C as a potential bladder tumour biomarker confirmed by surface plasmon resonance technique.
    Indian J Med Res. 2018;147:46-50.
    PubMed     Text format     Abstract available


    Indian J Pathol Microbiol

  15. AGARWAL P, Pasricha S, Gupta G, Sharma A, et al
    Urothelial carcinoma of urinary bladder with exclusive heterologous component of epithelioid rhabdomyosarcoma at metastatic site.
    Indian J Pathol Microbiol. 2018;61:258-260.
    PubMed     Text format     Abstract available


    Int J Mol Sci

  16. RABIEN A, Ratert N, Hogner A, Erbersdobler A, et al
    Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available

  17. FUKUSHIMA H, Takemura K, Suzuki H, Koga F, et al
    Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    J Clin Neurosci

  18. WAPSHOTT T, Schammel CMG, Schammel DP, Rezeanu L, et al
    Primary undifferentiated sarcoma of the meninges: A case report and comprehensive review of the literature.
    J Clin Neurosci. 2018;54:128-135.
    PubMed     Text format     Abstract available


    J Cutan Pathol

  19. PELLETIER D, O'Donnell M, Stone MS, Liu V, et al
    Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma.
    J Cutan Pathol. 2018 Feb 27. doi: 10.1111/cup.13138.
    PubMed     Text format     Abstract available


    J Vet Intern Med

  20. SMITH FL, Magdesian KG, Michel AO, Vaughan B, et al
    Equine idiopathic hemorrhagic cystitis: Clinical features and comparison with bladder neoplasia.
    J Vet Intern Med. 2018;32:1202-1209.
    PubMed     Text format     Abstract available


    J Vis Exp

  21. WANG Y, Day ML, Simeone DM, Palmbos PL, et al
    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer.
    J Vis Exp. 2018;.
    PubMed     Text format     Abstract available


    Medicine (Baltimore)

  22. YIN X, Xiong W, Wang Y, Tang W, et al
    Association of CYP2E1 gene polymorphisms with bladder cancer risk: A systematic review and meta-analysis.
    Medicine (Baltimore). 2018;97:e11910.
    PubMed     Text format     Abstract available

  23. LIU XP, Yin XH, Meng XY, Yan XH, et al
    DHCR24 predicts poor clinicopathological features of patients with bladder cancer: A STROBE-compliant study.
    Medicine (Baltimore). 2018;97:e11830.
    PubMed     Text format     Abstract available


    Mol Cancer

  24. ZHAN Y, Du L, Wang L, Jiang X, et al
    Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
    Mol Cancer. 2018;17:142.
    PubMed     Text format     Abstract available


    Mol Med Rep

  25. LI Y, Quan J, Pan X, Zhou J, et al
    Suppressing cell growth and inducing apoptosis by inhibiting miR23a5p in human bladder cancer.
    Mol Med Rep. 2018 Oct 2. doi: 10.3892/mmr.2018.9527.
    PubMed     Text format     Abstract available


    Onco Targets Ther

  26. STENEHJEM DD, Tran D, Nkrumah MA, Gupta S, et al
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
    Onco Targets Ther. 2018;11:5973-5989.
    PubMed     Text format     Abstract available

  27. GAO Q, Liu Y, Xie H, Zhong Y, et al
    Lentivirus-mediated shRNA targeting MUTYH inhibits malignant phenotypes of bladder cancer SW780 cells.
    Onco Targets Ther. 2018;11:6101-6109.
    PubMed     Text format     Abstract available


    Oncol Rep

  28. WU K, Mu XY, Jiang JT, Tan MY, et al
    miRNA26a5p and miR26b5p inhibit the proliferation of bladder cancer cells by regulating PDCD10.
    Oncol Rep. 2018 Sep 26. doi: 10.3892/or.2018.6734.
    PubMed     Text format     Abstract available


    Urol Int

  29. BOSSCHIETER J, Nieuwenhuijzen JA, Hentschel A, Vis AN, et al
    Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial.
    Urol Int. 2018 Sep 28:1-8. doi: 10.1159/000493159.
    PubMed     Text format     Abstract available

  30. KRAJEWSKI W, Zdrojowy R, Dembowski J, Poletajew S, et al
    The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2018 Sep 28:1-9. doi: 10.1159/000491642.
    PubMed     Text format     Abstract available


    Urology

  31. BUCHSER D, Zapatero A, Rogado J, Talaya M, et al
    LONG TERM OUTCOMES AND PATTERNS OF FAILURE FOLLOWING TRIMODALITY TREATMENT WITH BLADDER PRESERVATION FOR INVASIVE BLADDER CANCER.
    Urology. 2018 Sep 25. pii: S0090-4295(18)30966.
    PubMed     Text format     Abstract available


    World J Urol

  32. MOSCHINI M, Zaffuto E, Karakiewicz P, Mattei A, et al
    The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer.
    World J Urol. 2018 Oct 1. pii: 10.1007/s00345-018-2504.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: